Table 1. Patient characteristics.
| European Americans | African Americans | Hispanics | p value | |
|---|---|---|---|---|
| No (platelet analysis) | 984 | 201 | 99 | |
| Gender (n, %) | 608 (62%) | 121 (60%) | 63 (64%) | 0.8387 |
| Age, yrs* | 48 (44-52) | 50 (47-54) | 46 (39-51) | <0.0001 |
| BMI, kg/m2 | 27.4 (24.8-30.4) | 29.3 (26.6-32.6) | 28.6 (25.1-32.8) | <0.0001 |
| METAVIR fibrosis stage (n, %) | 873 (89%) | 183 (91%) | 85 (86%) | 0.3886 |
| Minimal (F0-2) | 111 (11%) | 18 (9%) | 14 (14%) | |
| Advanced (F3-4) | ||||
| RBV starting dose, mg/kg | 13.2 (12.4-14.1) | 12.8 (12.1-13.7) | 13.6 (12.5-14.7) | 0.0004 |
| RBV starting dose (n, %) | 0.0065 | |||
| 800 mg | 86 (9%) | 4 (2%) | 6 (6%) | |
| 1000 mg | 373 (38%) | 65 (32%) | 41 (41%) | |
| 1200 mg | 463 (47%) | 118 (59%) | 44 (44%) | |
| 1400 mg | 62 (6%) | 14 (7%) | 8 (8%) | |
| PegIFN starting dose (n, %) | ||||
| PegIFN-α-2b 1.0 | 332 (34%) | 71 (35%) | 31 (31%) | 0.8532 |
| PegIFN-α-2b 1.5 | 321 (33%) | 62 (31%) | 37 (37%) | |
| PegIFN-α-2a | 331 (34%) | 68 (34%) | 31 (31%) | |
| Baseline Pl count (×109/L) | 225 (184-269) | 228 (184-273) | 230 (186-275) | 0.8977 |
| Baseline Pl count <100×109/L | 17 (1.7%) | 2 (1%) | 1 (1%) | 0.6724 |
| Wk 4 Pl reduction (×109/L) | 37 (11-72) | 28 (0-61) | 26 (2-65) | 0.0052 |
| Wk 4 Pl count (n, %) | ||||
| <75×109/L | 24 (2%) | 4 (2%) | 0 (0%) | 0.2796 |
| <50×109/L | 2 (<1%) | 0 (0%) | 0 (0%) | 0.7369 |
| <25×109/L | 0 (0%) | 0 (0%) | 0 (0%) | 1.0000 |
| No (ANC analysis) | 991 | 203 | 98 | |
| Baseline ANC count (/mm3) | 3.65 (2.96-4.68) | 3.04 (2.14-4.04) | 3.36 (2.77-4.24) | <0.0001 |
| Week 4 ANC reduction (/mm3) | 2.0 (1.34-2.68) | 1.22 (0.61-1.97) | 1.72 (1.0-2.38) | <0.0001 |
| <1.0/mm3 (n, %) | 124 (13%) | 26 (13%) | 12 (12%) | 0.9892 |
| <0.75/mm3 (n, %) | 30 (3%) | 8 (4%) | 1 (1%) | 0.3816 |
| <0.5/mm3 (n, %) | 2 (<1%) | 2 (1%) | 0 (0%) | 0.1588 |
*
Continuous data are presented as median (25th – 75th centile).